Ascelia Pharma's CFO to Leave in August

MT Newswires · 2d ago
08:43 AM EDT, 07/15/2026 (MT Newswires) -- Ascelia Pharma (ACE.ST) said Wednesday that Chief Financial Officer Anton Hansson will leave the company in the latter part of August. The Swedish oncology-focused biotechnology company will trim its cost base and focus on bringing Orviglance to patients in light of the organizational change and cost-cutting initiatives. Orviglance is a novel oral contrast agent designed for magnetic resonance imaging of the liver.